Alison C Tree

Oct 13, 2024 | urotoday.com | Alison C Tree

Read the Full Video TranscriptZachary Klaassen: Hi, my name is Zach Klaassen. I'm a Urologic Oncologist at the Georgia Cancer Center in Augusta, Georgia. I'm delighted to be joined by Dr. Alison Tree, who is a clinical oncologist at the Royal Marsden Hospital in the UK. Alison, thanks so much for joining us today. Alison Tree: Oh, my pleasure. Thanks for having me on. Zachary Klaassen: We're doing a nice collection of discussions around ESTRO 2024.

May 22, 2024 | europeanurology.com | Adam B. Weiner |Andrew Armstrong |Alberto Bossi |La Garenne Colombes |Philip Cornford |Felix Feng | +9 more

Abstract Biochemical recurrence (BCR) after primary definitive treatment for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with worse oncologic outcomes, risk factors that impact outcomes can vary significantly, necessitating avenues for risk stratification. We sought to identify prognostic risk factors at the time of recurrence after primary radical prostatectomy or radiotherapy, and prior to salvage treatment(s), associated with adverse oncologic outcomes.

Jan 12, 2024 | thegreenjournal.com | Lu Han |Richard M. Sullivan |Alison C Tree

Highlights•The study includes public transport and car travel times for all patients (c.40,000 men) treated with surgery or radiotherapy for prostate cancer. •We show that analyses of access using car travel times alone significantly under-estimate travel times for patients reliant on public transport. •Travel times are greatest by public transport or car for patients living in rural and the most socially deprived areas.